$-0.40 EPS Expected for Exact Sciences Corporation (EXAS)

October 2, 2018 - By Richard Conner

Exact Sciences Corporation (NASDAQ:EXAS) LogoInvestors sentiment decreased to 1.01 in Q2 2018. Its down 0.14, from 1.15 in 2018Q1. It turned negative, as 44 investors sold Exact Sciences Corporation shares while 97 reduced holdings. 62 funds opened positions while 80 raised stakes. 100.39 million shares or 1.50% less from 101.92 million shares in 2018Q1 were reported.
Stifel Financial reported 15,906 shares or 0% of all its holdings. Sg Americas Securities Limited Com accumulated 132,726 shares or 0.07% of the stock. Kames Capital Public Limited Liability Co holds 784,068 shares or 1.15% of its portfolio. Landscape Cap Ltd Liability Corp accumulated 0.02% or 4,948 shares. State Board Of Administration Of Florida Retirement Sys reported 0.03% in Exact Sciences Corporation (NASDAQ:EXAS). Lpl Ltd Limited Liability Company invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Greenwood Capital Assoc Llc invested in 7,441 shares or 0.1% of the stock. Westpac Banking reported 173,312 shares. Envestnet Asset Mngmt invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Glob X Mngmt Limited Liability Co accumulated 1,592 shares. Sit Inv Assocs Inc owns 33,300 shares. 7,437 are owned by Element Ltd Limited Liability Company. Redwood Invests Ltd Liability invested in 256,266 shares. Howe And Rusling invested in 20 shares. Signalpoint Asset Mngmt Lc accumulated 0.18% or 6,408 shares.

Since April 10, 2018, it had 0 insider buys, and 9 sales for $1.94 million activity. The insider Carey Thomas D. sold $201,713. Doyle James Edward had sold 1,318 shares worth $77,577. Fallon John A. sold $139,675 worth of stock or 2,373 shares. Zanotti Katherine S also sold $325,440 worth of Exact Sciences Corporation (NASDAQ:EXAS) on Thursday, April 12.

Analysts expect Exact Sciences Corporation (NASDAQ:EXAS) to report $-0.40 EPS on October, 29.They anticipate $0.17 EPS change or 73.91 % from last quarter’s $-0.23 EPS. After having $-0.30 EPS previously, Exact Sciences Corporation’s analysts see 33.33 % EPS growth. The stock increased 0.35% or $0.28 during the last trading session, reaching $79.2. About 626,362 shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 76.39% since October 2, 2017 and is uptrending. It has outperformed by 60.77% the S&P500.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 7 analysts covering Exact Sciences (NASDAQ:EXAS), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Exact Sciences had 16 analyst reports since April 3, 2018 according to SRatingsIntel. On Wednesday, June 6 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Outperform” rating by Robert W. Baird on Tuesday, June 5. The rating was maintained by Robert W. Baird with “Outperform” on Tuesday, September 11. Cowen & Co maintained the stock with “Buy” rating in Monday, June 18 report. Jefferies maintained it with “Buy” rating and $57 target in Thursday, August 2 report. Canaccord Genuity maintained it with “Buy” rating and $7500 target in Friday, June 15 report. Canaccord Genuity maintained the stock with “Buy” rating in Friday, April 27 report. The company was upgraded on Tuesday, April 3 by BTIG Research. The firm has “Outperform” rating given on Thursday, August 23 by Robert W. Baird. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Canaccord Genuity on Thursday, May 31.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $9.72 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More important recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Seekingalpha.com which released: “Canaccord bullish on medical diagnostic firms” on September 14, 2018, also Benzinga.com published article titled: “The Daily Biotech Pulse: Verastem’s Chinese Duvelisib Licensing Deal, Aldeyra’s Positive Dry Eye Disease Drug Trial”, Fool.com published: “3 Stocks That Turned $1000 Into $23000 or More in 10 Years” on September 27, 2018. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) was released by: Seekingalpha.com and their article: “EXACT Sciences Is Defying Gravity” with publication date: September 04, 2018.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.